Application of pantothenic acid in the preparation of anti-caries preparations related to Streptococcus mutans and anti-caries preparations containing pantothenic acid

Abstract

The present invention discloses the use of pantothenic acid in the preparation of anticaries preparations related to Streptococcus mutans, and anticaries preparations containing pantothenic acid. The invention belongs to the field of biomedicine technology. The anticaries preparations related to Streptococcus mutans include an acid production inhibitor for Streptococcus mutans, a growth inhibitor for Streptococcus mutans, an inhibitor of cariogenic toxins of Streptococcus mutans, and an inhibitor of interspecies competition of Streptococcus mutans. Pantothenic acid can be used to influence the acid production, growth, production of cariogenic toxins, and interspecies competition of Streptococcus mutans, thereby maintaining the balance of the oral microecology.

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and particularly relates to the application of pantothenic acid in the preparation of anticaries preparations related to Streptococcus mutans and anticaries preparations containing pantothenic acid. Background Art

[0002] Dental caries is a chronic, progressive, and destructive disease of the hard tissues of the teeth. Besides affecting local functions such as chewing, speech, and aesthetics, it also impacts patients' social interactions, self-esteem, and psychological well-being. It can even aggravate or induce systemic diseases, severely impacting oral health and overall health. Despite the significant health and economic burden of dental caries on society, current treatment strategies have not significantly reduced the incidence of dental caries. Therefore, reducing the risk of dental caries in high-risk populations and preventing dental caries are of great value, both in promoting oral health for the general population and in achieving socioeconomic benefits.

[0003] Dental plaque biofilms are the primary bacterial presence in the oral cavity and are the initiating factor in the development of dental caries. Epidemiological studies have found that the detection rate of Streptococcus mutans in dental plaque biofilms is positively correlated with the incidence of dental caries, making S. mutans the primary dental caries-associated bacterium. S. mutans produces acid, which lowers the pH in the plaque biofilm microenvironment, causing demineralization of dental hard tissue and ultimately leading to dental caries. Furthermore, during the initial stages of biofilm formation, the proportion of S. mutans is very low. Furthermore, plaque biofilms are multispecies, dynamic microecological communities. The ability of S. mutans to rapidly adapt to the complex and changing plaque biofilm environment at such a low abundance is a prerequisite for its proliferation and ultimately its cariogenic effects. This is closely related to its interspecies competitive ability, including its ability to inhibit the growth of other commensal bacteria through the production of bacteriocins, as well as its ability to adapt to oxidative stress (a major stressor in biofilms). Therefore, inhibiting the acid production and interspecies competitive ability of S. mutans is crucial for maintaining oral microecological balance and dental health.

[0004] However, the current clinical prevention and treatment strategy for dental caries is not to intervene in the progression of dental caries with drugs, but to passively treat the outcome of dental caries, namely, cavities. Existing dental caries prevention methods include the use of fluorides such as sodium fluoride and silver ammonium fluoride. Fluoride ions in fluoride can replace hydroxyl groups in tooth hydroxyapatite through ion exchange to form fluorapatite, which increases the hardness of the tooth surface, reduces the solubility of enamel in acidic environments, inhibits the uptake and utilization of glucose by Streptococcus mutans, and promotes the remineralization of enamel. However, its disadvantages are: (1) Excessive intake of fluoride during the formation and development of permanent tooth germs (especially at the age of 2-3) can lead to dental fluorosis; (2) With the widespread use of fluoride, some Streptococcus mutans have shown resistance to fluoride, which greatly reduces the dental caries prevention effect of fluoride.

[0005] In the study "Research Progress on the Molecular Mechanism of Acid Resistance of Streptococcus mutans" (International Journal of Stomatology, 2008, Vol. 5, pp. 534-536), Lu Shijun et al. analyzed the mechanism of action of the related genes and related proteins of Streptococcus mutans: ropA gene, BrpA gene, agmatine deiminase, ffh gene, uvrA gene, relA gene, luxS gene, GroE and DnaK protein, which affect the acid resistance of Streptococcus mutans. This is expected to provide ideas for the prevention of dental caries at the molecular level.

[0006] Pantothenic acid, also known as vitamin B5 or pantothenic acid, is odorless, slightly bitter, and acidic. It helps produce antibodies and plays a vital role in maintaining healthy hair, skin, and blood. A deficiency can cause symptoms such as tachycardia, fatigue, nausea, symmetrical dermatitis, and insomnia. However, there are currently no reports of using pantothenic acid for dental caries prevention at the molecular level. Summary of the Invention

[0007] The present invention aims to provide the use of pantothenic acid in the preparation of anticaries preparations related to Streptococcus mutans. Pantothenic acid can be used to influence the acid production, growth, cariogenic toxin production, and interspecies competition of Streptococcus mutans, thereby maintaining the balance of the oral microecology. To this end, the present invention also provides anticaries preparations containing pantothenic acid.

[0008] The present invention is achieved through the following technical solution: use of pantothenic acid in the preparation of an anti-caries preparation related to Streptococcus mutans, wherein the anti-caries preparation related to Streptococcus mutans includes an acid production inhibitor of Streptococcus mutans, a growth inhibitor of Streptococcus mutans, an inhibitor of cariogenic toxin of Streptococcus mutans, and an inhibitor of interspecies competition of Streptococcus mutans.

[0009] The acid production inhibitor of Streptococcus mutans is achieved by inhibiting the expression of acid production-related genes of Streptococcus mutans through pantothenic acid, and the acid production-related genes include: lpdA, SMU_RS07275, SMU_RS00660, SMU_RS08995, SMU_RS06325, SMU_RS06470, SMU_RS06305, pta, pflB, and ldh.

[0010] The growth inhibitor of Streptococcus mutans is achieved by inhibiting the expression of oxidative adaptation-related genes of Streptococcus mutans by pantothenic acid, and the oxidative adaptation-related genes include SMU_RS01380, SMU_RS01385, ulaG, SMU_RS01370, SMU_RS01365, and SMU_RS01360.

[0011] The cariogenic toxin inhibitor of Streptococcus mutans is achieved by inhibiting the expression of bacteriocin-producing related genes of Streptococcus mutans through pantothenic acid, and the bacteriocin-producing related genes include SMU_RS08675, SMU_RS08695, SMU_RS08650, SMU_RS08645, SMU_RS08670, SMU_RS00755, SMU_RS00750, and SMU_RS08700.

[0012] The interspecies competition inhibitor of Streptococcus mutans is achieved by inhibiting the expression of acid production-related genes, oxidation adaptation-related genes and bacteriocin production-related genes of Streptococcus mutans.

[0013] Acid production-related genes include: lpdA, SMU_RS07275, SMU_RS00660, SMU_RS08995, SMU_RS06325, SMU_RS06470, SMU_RS06305, pta, pflB, ldh;

[0014] Genes related to oxidative adaptation include SMU_RS01380, SMU_RS01385, ulaG, SMU_RS01370, SMU_RS01365, and SMU_RS01360;

[0015] Bacteriocin-producing related genes include SMU_RS08675, SMU_RS08695, SMU_RS08650, SMU_RS08645, SMU_RS08670, SMU_RS00755, SMU_RS00750, and SMU_RS08700.

[0016] The interspecies competition includes interspecies competition between Streptococcus mutans, Streptococcus gordonii and Streptococcus sanguis.

[0017] The present invention also provides an anti-caries preparation containing pantothenic acid, including but not limited to: the above-mentioned Streptococcus mutans acid production inhibitor, Streptococcus mutans growth inhibitor, Streptococcus mutans cariogenic toxin inhibitor and Streptococcus mutans interspecies competition inhibitor.

[0018] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0019] (1) The present invention provides a new application of pantothenic acid in treating Streptococcus mutans to prevent dental caries. Pantothenic acid can inhibit the acid production, oxygen tolerance and interspecies competition of Streptococcus mutans, and regulate the oral microecology, which is expected to achieve dental caries prevention treatment at the molecular level.

[0020] (2) The present invention uses pantothenic acid as an active substance. Since pantothenic acid is a vitamin widely present in a variety of foods in nature, it is safe and non-toxic and will not cause abnormalities in the process of tooth development;

[0021] (3) When preparing the cariogenic toxin inhibitor of Streptococcus mutans in the present invention, the concentration of pantothenic acid required to inhibit the cariogenic toxicity of Streptococcus mutans is relatively low, but the inhibitory effect is significant.

[0022] (4) The pantothenic acid of the present invention can not only inhibit the cariogenic toxicity of Streptococcus mutans, but also weaken its ability to adapt to the environment;

[0023] (5) The present invention utilizes pantothenic acid to prepare an interspecies competition inhibitor for Streptococcus mutans, which can put the pantothenic acid-treated Streptococcus mutans at a disadvantage when competing with oral resident bacteria including Streptococcus gordonii and Streptococcus sanguis, thereby increasing the oral resident flora, reducing the effect of cariogenic bacteria, and regulating the oral microecology. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is the pH measurement curve for investigating the effect of pantothenic acid on the acid production performance of Streptococcus mutans in Example 1.

[0025] Figure 2 This is a comparison chart of the acid production-related gene expression of Streptococcus mutans in Example 1.

[0026] Figure 3 This is the inhibitory effect of Streptococcus gordonii on Streptococcus mutans in Example 2.

[0027] Figure 4 This is the inhibitory effect of Streptococcus sanguis on Streptococcus mutans in Example 2.

[0028] Figure 5 This is a comparison of the inhibition distances of Streptococcus gordonii and Streptococcus sanguinis against Streptococcus mutans treated with and without pantothenic acid in Example 2.

[0029] Figure 6 This is a comparison chart of the expression of oxidative adaptation-related genes in Streptococcus mutans in Example 2.

[0030] Figure 7 This is the inhibitory effect of Streptococcus mutans on the growth of Streptococcus gordonii in Example 3.

[0031] Figure 8 This is the inhibitory effect of Streptococcus mutans on the growth of Streptococcus sanguis in Example 3.

[0032] Figure 9 This is a comparison of the growth inhibition distances of Streptococcus mutans on Streptococcus gordonii and Streptococcus sanguis in Example 3, whether or not it was treated with pantothenic acid.

[0033] Figure 10 This is a comparison chart of the expression of bacteriocin-related genes in Streptococcus mutans in Example 3. DETAILED DESCRIPTION

[0034] The objectives, technical solutions and beneficial effects of the present invention are further described in detail below.

[0035] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the claimed invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs.

[0036] The present invention is the first to use pantothenic acid to prepare an anti-caries preparation related to Streptococcus mutans, which is a new use of pantothenic acid. Specifically, pantothenic acid is used to achieve anti-caries treatment by affecting the acid production, growth performance, cariogenic toxin production and the absence of interspecies competition of Streptococcus mutans. It can regulate the oral microecology, is safe and non-toxic to use, and does not cause abnormalities in the tooth development process, thereby achieving the purpose of reducing cariogenic bacteria at the molecular level.

[0037] Specifically, the present invention can inhibit the expression of acid-producing genes in Streptococcus mutans through pantothenic acid, thereby affecting the acid production of Streptococcus mutans. Therefore, it can be used to prepare anti-caries preparations related to Streptococcus mutans, such as an acid production inhibitor for Streptococcus mutans. The acid-producing genes include: lpdA, SMU_RS07275, SMU_RS00660, SMU_RS08995, SMU_RS06325, SMU_RS06470, SMU_RS06305, pta, pflB, and ldh.

[0038] The present invention can inhibit the expression of genes related to oxidative adaptation of Streptococcus mutans through pantothenic acid, thereby affecting the growth performance of Streptococcus mutans. Therefore, it can be used to prepare anti-caries preparations related to Streptococcus mutans, such as growth inhibitors of Streptococcus mutans. The genes related to oxidative adaptation include SMU_RS01380, SMU_RS01385, ulaG, SMU_RS01370, SMU_RS01365, and SMU_RS01360.

[0039] The present invention can inhibit the expression of bacteriocin-producing genes in Streptococcus mutans through pantothenic acid, thereby reducing the production of cariogenic toxins by Streptococcus mutans. Therefore, it can be used to prepare anti-caries preparations related to Streptococcus mutans, such as inhibitors of cariogenic toxins of Streptococcus mutans. The bacteriocin-producing genes include SMU_RS08675, SMU_RS08695, SMU_RS08650, SMU_RS08645, SMU_RS08670, SMU_RS00755, SMU_RS00750, and SMU_RS08700.

[0040] Furthermore, based on the effect of pantothenic acid on the expression of the above-mentioned genes (acid production-related genes, oxidative adaptation-related genes, and bacteriocin production-related genes) in Streptococcus mutans, interspecies competition of Streptococcus mutans can be inhibited. Therefore, it can also be used to prepare an interspecies competition inhibitor of Streptococcus mutans, that is, to achieve interspecies competition inhibition of Streptococcus mutans in Streptococcus gordonii and Streptococcus oralis, so that Streptococcus mutans is at a disadvantage when competing with oral resident bacteria including Streptococcus gordonii and Streptococcus oralis, thereby achieving the purpose of regulating the oral microecology and reducing cariogenic bacteria to achieve caries prevention treatment.

[0041] The present invention will be further described in detail below with reference to the examples, but the embodiments of the present invention are not limited thereto.

[0042] Example 1: Effect of pantothenic acid on the acid production of Streptococcus mutans

[0043] Experimental Materials:

[0044] 37 g / L brain heart infusion broth (BHI) medium; standard strain of Streptococcus mutans UA159; pantothenic acid (vitamin B5, VB5); PPB (0.35 g / L K2HPO4·3H2O, 0.13 g / L KH2PO4, 2.8 g / L KCl, 0.255 g / LMgCl2·6H2O, pH = 7) buffer; glucose; 15 ml centrifuge tube.

[0045] Experimental methods:

[0046] Single mutans Streptococcus colonies were selected and incubated in BHI medium in a 37°C incubator containing 5% CO2 overnight for approximately 16 hours. The culture was then diluted 1:10 with BHI and incubated in a 37°C incubator containing 5% CO2 for approximately 2.5 hours. The absorbance of the mutans Streptococcus culture at 600 nm was approximately 0.5. Five experimental groups were divided into each group. 2.5 ml of the culture was transferred to a 15 ml centrifuge tube and centrifuged at 4000 rpm for 10 minutes. The supernatant was discarded. 2.5 ml of PPB buffer was added, and the tubes were centrifuged again at 4000 rpm for 10 minutes. The supernatant was discarded and the cells were divided into 0 mM (control), 2 mM, 4 mM, 6 mM, and 8 mM VB5 groups. The cells were resuspended in 2.5 ml of PPB buffer containing the corresponding concentration of pantothenic acid and 1% glucose. The pH was measured every 5 minutes for 60 minutes.

[0047] The experimental results are shown in Figure 1 .

[0048] like Figure 1As shown in the figure, after adding PPB buffer containing glucose, Streptococcus mutans quickly produced acid and the pH dropped significantly. After adding pantothenic acid, the acid production rate of Streptococcus mutans was significantly slowed down and the acid production ability was weakened. Moreover, with the increase of pantothenic acid concentration, the acid production rate of Streptococcus mutans became slower and slower. It can be seen that pantothenic acid has a concentration-dependent inhibitory effect on the acid production of Streptococcus mutans.

[0049] Furthermore, the expression of acid production-related genes of Streptococcus mutans in the control group (0 mM VB5 group) and the 8 mM pantothenic acid group was measured by real-time quantitative polymerase chain reaction (RT-qPCR). The measurement results are shown in Figure 2 .

[0050] like Figure 2 As shown in the data, the acid production-related genes lpdA, SMU_RS07275, SMU_RS00660, SMU_RS08995, SMU_RS06325, SMU_RS06470, SMU_RS06305, pta, pflB, and ldh in the 8 mM pantothenic acid group were lower than those in the 0 mM VB5 group. This indicates that pantothenic acid can inhibit the expression of acid production-related genes in Streptococcus mutans.

[0051] Example 2: Effect of Pantothenic Acid on the Oxidative Adaptability of Streptococcus mutans (Experiment on Pantothenic Acid Weakening the Resistance of Streptococcus mutans to Symbiotic Bacteria with Hydrogen Peroxide Production)

[0052] Experimental Materials:

[0053] 37 g / L brain heart infusion broth (BHI) medium; 18.5 g / L brain heart infusion broth (1 / 2BHI) medium; 18.5 g / L brain heart infusion broth medium + 1.5% agar (1 / 2BHIA) plate; Streptococcus mutans standard strain UA159 (Sm); Streptococcus gordonii (Sg); Streptococcus sanguis (Ss); pantothenic acid (vitamin B5, VB5); glycine buffer (7.5 g / L, pH = 7).

[0054] Experimental methods:

[0055] Streptococcus mutans (Sm), Streptococcus gordonii (Sg), and Streptococcus sanguis (Ss) were cultured in BHI medium overnight in a 37°C incubator containing 5% carbon dioxide for approximately 16 hours. Sg and Ss were diluted 1:10 with 1 / 2 BHI and incubated in a 37°C incubator with 5% carbon dioxide for approximately 3.5 hours and 3 hours, respectively, until the absorbance at 600 nm of Sg and Ss reached approximately 0.5.

[0056] When Streptococcus mutans was diluted 1:10 using 1 / 2BHI, it was divided into two groups: one group was a control (0 mM VB5) group, which was diluted with 1 / 2BHI; the other group was a VB5 group, which was diluted with 1 / 2BHI and added with pantothenic acid to a concentration of 8 mM. The cells were cultured in a 37°C 5% carbon dioxide incubator for approximately 3.5 hours. The absorbance of the Streptococcus mutans culture solution at 600 nm was approximately 0.5. The cells were then centrifuged at 4000 rpm for 10 minutes, the supernatant was discarded, and an equal volume of glycine buffer was added for resuspending. The cells were centrifuged again at 4000 rpm for 10 minutes, the supernatant was discarded, and an equal volume of glycine buffer was added for later use.

[0057] On a 1 / 2 BHIA plate, 8 μL of each of Sg and Ss was added to form a circular droplet. After the droplet lay flat for 30 minutes, the plate was incubated in a 37°C incubator with 5% CO2 for 24 hours. Simultaneously, on another 1 / 2 BHIA plate, Streptococcus mutans treated with different treatments and 8 μL of Sg or Ss were spotted simultaneously. The two droplets formed two circles approximately 1 cm apart and 0.9 cm in diameter. The plates were then incubated in a 37°C incubator with 5% CO2 for 48 hours.

[0058] A single colony of Streptococcus mutans was selected and placed in BHI medium and cultured overnight in a 37°C incubator containing 5% carbon dioxide for about 16 hours. Then, when diluted 1:10 with 1 / 2BHI, the colony was divided into two groups: a control (0 mM VB5) group, which was diluted with 1 / 2BHI; and a VB5 group, which was diluted with 1 / 2BHI and added with pantothenic acid to a concentration of 8 mM. The colony was further cultured in a 37°C 5% carbon dioxide incubator for about 3.5 hours. The absorbance of the Streptococcus mutans culture solution at 600 nm was approximately 0.5. The colony was then centrifuged at 4000 rpm for 10 minutes, the supernatant was discarded, and an equal volume of glycine buffer was added for resuspending. The colony was centrifuged again at 4000 rpm for 10 minutes, the supernatant was discarded, and an equal volume of glycine buffer was added for later use.

[0059] Take out the 1 / 2 BHIA plate spotted with Sg or Ss the day before, and spot 8 μL of untreated Sm and 8 μL of Sm treated with 8 mM VB5 next to the Sg or Ss, respectively, so that the distance between the centers of the two circles formed by the droplets is about 1 cm and the diameter of the two circles is about 0.9 cm. Place it flat for 30 minutes and then continue to culture in a 37°C 5% carbon dioxide incubator for 24 hours.

[0060] The growth of Streptococcus mutans (Sm), Streptococcus gordonii (Sg) and Streptococcus sanguinis (Ss) in the experimental group and the control (0 mM VB5) group after culture was detected by calculating the inhibition distance. Figure 3 、 Figure 4 and Figure 5 .

[0061] like Figure 3 、 Figure 4 and Figure 5 As shown, after the experimental group was treated with 8 mM pantothenic acid, the inhibitory effect of Streptococcus gordonii and Streptococcus sanguis on Streptococcus mutans was enhanced, indicating that the oxidative adaptability of Streptococcus mutans to hydrogen peroxide produced by Streptococcus gordonii and Streptococcus sanguis was weakened after pantothenic acid treatment.

[0062] Furthermore, the expression of oxidative adaptation-related genes of Streptococcus mutans in the experimental group and the control (0 mM VB5) group was measured by real-time quantitative polymerase chain reaction (RT-qPCR). The measurement results are shown in Figure 6 .

[0063] like Figure 6 As shown in the figure, the oxidative adaptation-related genes SMU_RS01380, SMU_RS01385, ulaG, SMU_RS01370, SMU_RS01365, and SMU_RS01360 in the experimental group were all lower than those in the control (0 mM VB5) group. This shows that pantothenic acid can inhibit the expression of oxidative adaptation-related genes in Streptococcus mutans.

[0064] Example 3: Effect of Pantothenic Acid on the Secretion of Bacteria by Streptococcus mutans (Experiment in which Pantothenic Acid Inhibits the Bacteriocin Production Capacity of Streptococcus mutans, Weakening Its Inhibitory Effect on Symbiotic Bacteria)

[0065] Experimental Materials:

[0066] 37 g / L brain heart infusion broth (BHI) medium; 37 g / L brain heart infusion broth medium + 1.5% agar (BHIA) plate; Streptococcus mutans standard strain UA159; Streptococcus gordonii (Sg); Streptococcus sanguis (Ss); pantothenic acid (vitamin B5, VB5).

[0067] Experimental methods:

[0068] Streptococcus mutans (Sm), Streptococcus gordonii (Sg), and Streptococcus sanguis (Ss) were cultured in BHI medium overnight in a 37°C incubator containing 5% CO2 for approximately 16 hours. Sg and Ss were diluted 1:10 in BHI and incubated in a 37°C incubator with 5% CO2 for approximately 2.5 hours and 2 hours, respectively, until the absorbance at 600 nm of Sg and Ss reached approximately 0.5.

[0069] Mutans Streptococcus was diluted 1:10 with BHI and divided into two groups: a control group (A1) diluted with BHI; and a VB5 group (B1). Pantothenic acid was added to the BHI dilution to a concentration of 8 mM. The cultures were then incubated in a 37°C, 5% CO2 incubator for approximately 2.5 hours. The absorbance of the mutans Streptococcus culture at 600 nm was approximately 0.5. 8 μL of the mutans Streptococcus treated with each sample was added onto a BHIA plate. The droplet formed a circular shape and was allowed to rest for 30 minutes. The plates were then incubated in a 37°C, 5% CO2 incubator for 24 hours.

[0070] At the same time, 8 μL of Sg and Ss were spotted on another BHIA plate, and then 8 μL of the mutans Streptococcus of the control group and the mutans Streptococcus treated with 8 mM VB5 were spotted next to Sg and Ss respectively. The distance between the centers of the two circles formed by the two droplets was about 1 cm, and the diameters of the two circles were about 0.9 cm. The plates were placed in a 37°C 5% carbon dioxide incubator and cultured for 48 h.

[0071] Single colonies of Streptococcus gordonii and Streptococcus sanguinis were selected and placed in BHI medium and cultured overnight in a 37°C incubator containing 5% carbon dioxide for about 16 hours. They were then diluted 1:10 with BHI and continued to be cultured in a 37°C 5% carbon dioxide incubator for about 2.5 hours and 2 hours, respectively, until the absorbance values ​​of Sg and Ss at 600 nm were approximately 0.5.

[0072] Take out the BHIA plate that had been spotted with Streptococcus mutans with different treatments the day before, and spot 8 μL of Sg and Ss next to the Streptococcus mutans, so that the distance between the centers of the two circles formed by the droplets is about 1 cm and the diameter of the two circles is about 0.9 cm. After lying flat for 30 minutes, continue to culture in a 37°C 5% carbon dioxide incubator for 24 hours.

[0073] The growth of Streptococcus mutans (Sm), Streptococcus gordonii (Sg) and Streptococcus sanguinis (Ss) in the experimental and control groups after culture was detected by calculating the inhibition distance. Figure 7 、 Figure 8 and Figure 9 .

[0074] like Figure 7 、 Figure 8 and Figure 9 As shown, the mutans production of Streptococcus mutans in the experimental group after treatment with 8 mM pantothenic acid was less than that in the control group, which weakened the inhibitory effect of Streptococcus mutans on Streptococcus gordonii and Streptococcus sanguis.

[0075] Furthermore, the expression of bacteriocin-related genes of Streptococcus mutans in the experimental group and the control (0 mM VB5) group was measured by real-time quantitative polymerase chain reaction (RT qPCR). The measurement results are shown in Figure 10 .

[0076] like Figure 10 As shown in the data, the expression of bacteriocin-related genes SMU_RS08675, SMU_RS08695, SMU_RS08650, SMU_RS08645, SMU_RS08670, SMU_RS00755, SMU_RS00750, and SMU_RS08700 in the experimental group were lower than those in the control group (0 mM VB5). This indicates that pantothenic acid can inhibit the expression of bacteriocin-related genes in Streptococcus mutans.

[0077] In summary, treatment with 8 mM pantothenic acid enhanced the inhibitory effect of S. gordonii and S. sanguinis on S. mutans, indicating that pantothenic acid treatment weakened S. mutans's ability to adapt to the oxidative hydrogen peroxide produced by S. gordonii and S. sanguinis. 8 mM pantothenic acid treatment reduced mutagen production by S. mutans compared with the control, weakening the inhibitory effect of S. mutans on S. gordonii and S. sanguinis. Mutagen production by S. mutans inhibits S. gordonii and S. sanguinis, while hydrogen peroxide production by S. gordonii and S. sanguinis inhibits S. mutans. Interspecies competition exists between S. mutans and either S. gordonii or S. sanguinis. These results suggest that 8 mM pantothenic acid treatment weakens interspecies competition in S. mutans.

[0078] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Any simple modification or equivalent change made to the above embodiment based on the technical essence of the present invention shall fall within the scope of protection of the present invention.

Claims

1. Use of pantothenic acid in the preparation of a preparation for regulating oral microecological balance, characterized in that: The oral microecological regulator utilizes the following properties of pantothenic acid to regulate the oral microecological balance: (1) Pantothenic acid's inhibitory effect on Streptococcus mutans acid production; (2) Pantothenic acid's inhibitory effect on the growth of Streptococcus mutans; (3) The inhibitory effect of pantothenic acid on the cariogenic toxin of Streptococcus mutans; (4) Pantothenic acid inhibits interspecies competition against Streptococcus mutans.

2. The use according to claim 1, characterized in that: The ability of pantothenic acid to inhibit acid production in Streptococcus mutans is achieved by inhibiting the expression of acid production-related genes in Streptococcus mutans, including: lpdA 、 SMU_ RS07275 、 SMU_RS00660 、 SMU_RS08995 、 SMU_RS06325 、 SMU_RS06470 、 SMU_RS06305 、 pta 、 pfL 、 ldh .

3. The use according to claim 1, characterized in that: The growth inhibition of pantothenic acid on Streptococcus mutans is achieved by inhibiting the expression of oxidative adaptation-related genes of Streptococcus mutans, including SMU_ RS01380 、 SMU_RS01385 、 ulaG 、 SMU_RS01370 、 SMU_RS01365 、 SMU_RS01360 .

4. The use according to claim 1, characterized in that: The inhibitory effect of pantothenic acid on the cariogenic toxin of Streptococcus mutans is achieved by pantothenic acid inhibiting the expression of bacteriocin-related genes of Streptococcus mutans, including SMU_ RS08675 、 SMU_RS08695 、 SMU_RS08650 、 SMU_RS08645 、 SMU_RS08670 、 SMU_RS00755 、 SMU_ RS00750 、 SMU_RS08700 .

5. The use according to claim 1, characterized in that: The interspecific competition inhibition of pantothenic acid on Streptococcus mutans is achieved by inhibiting the expression of acid production-related genes, oxidative adaptation-related genes and bacteriocin production-related genes of Streptococcus mutans. Genes involved in acid production include: lpdA 、 SMU_RS07275 、 SMU_RS00660 、 SMU_RS08995 、 SMU_RS06325 、 SMU_RS06470 、 SMU_RS06305 、 pta 、 pfL 、 ldh ; Genes involved in oxidative adaptation include SMU_RS01380 、 SMU_RS01385 、 ulaG 、 SMU_RS01370 、 SMU_RS01365 、 SMU_RS01360 ; Bacteriocin-producing genes include SMU_RS08675 、 SMU_RS08695 、 SMU_RS08650 、 SMU_RS08645 、 SMU_ RS08670 、 SMU_RS00755 、 SMU_RS00750 、 SMU_RS08700 .

6. The use according to claim 5, characterized in that: The interspecies competition includes interspecies competition between Streptococcus mutans, Streptococcus gordonii and Streptococcus sanguis.

Images